Emerging and Evolving Biomarkers: HRD Score





Speaker:

Melinda Telli, MD

Moderator:

Kurtis Davies, PhD


This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.


Description: 

Homologous recombination deficiency score (HRD) includes assessment of loss of heterozygosity, large-scale state transitions, and telomeric allelic imbalance as an assessment of functional loss of homologous recombination repair. HRD score has been studied in multiple tumor types with the aim of predicting therapeutic response independent of homologous recombination repair gene mutation status. The scientific background, testing considerations, and clinical implications will be discussed in this presentation.

Learning Objectives: 


1. Describe the biological principles that underlie the relevance of HRD score, including the cellular signaling pathways and cellular processes involved.

2. Discuss the appropriate technical approaches and platforms for HRD score molecular diagnostic testing.

3. Outline the strengths and limitations of described testing approaches.

4. Apply HRD score information so as to order appropriate testing and interpret test results within a clinical context.

This webinar is part 2 of the Emerging and Evolving Biomarkers Series

This program has been supported through an educational grant from Bristol-Myers Squibb.

Recorded Date: July 21, 2020
Duration: 1 hr
Level of Instruction: Basic
CME/CMLE credit: 1.00 hour

Last Day to Claim CE Credit: December 31, 2022


How to claim credit: 

To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.

AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity. 

* Please note SAM credit is NOT available for this course.


AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.


Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.